Patients With Intransit Stage III/IV Melanoma

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Philogen
PhilogenItaly - Monteriggioni
1 program
1
Isolated inferior limb perfusionPhase 11 trial
Active Trials
NCT01213732Completed19Est. Sep 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PhilogenIsolated inferior limb perfusion

Clinical Trials (1)

Total enrollment: 19 patients across 1 trials

NCT01213732PhilogenIsolated inferior limb perfusion

Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma

Start: Oct 2008Est. completion: Sep 201119 patients
Phase 1Completed

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space